Wegovy Gets F.D.A. Approval for MASH
US$ 24.54
whats the difference between tirzepatide and retatrutide vs. Navigating the Weight Loss Maze:
Description
Survodutide has shown glycemic improvement in Phase 2 trials with T2D patients (up to 1.71 percentage point HbA1c reduction at 16 weeks with the 2.7 mg dose), but this data is from shorter, smaller studies
This third mechanism increases energy expenditure, which may explain why retatrutide shows greater weight loss in early clinical data (~2428% vs ~1621% for tirzepatide)
Others lose 2-3 pounds
Though still in its early stages, you can check with our Patient Support team about available funding options
